About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

EU PV for Retapamulin-Prescribing | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT01153828

EU PV for Retapamulin-Prescribing

Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the European Union (EU), retapamulin is approved for the treatment of imp...

Lead sponsor: GlaxoSmithKline•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•The study population will consist of all registered "research standard" patients on GPRD, as evaluated annually for five years. For each year of observation, the denominator of persons will be patients registered for at least one month during the prior calendar year. Hence, the five-year reporting period for distinct, non-overlapping, non-cumulative prescription use and will categorize persons by date of birth (mm/dd/year).

Exclusion Criteria

•Enrollment in GPRD of less than one month duration.

Related studies

COMPLETEDPhase 3

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT02090764 · Impetigo

COMPLETEDPhase 3

Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

NCT00133848 · Impetigo

COMPLETEDPhase 3

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

NCT01397461 · Impetigo

COMPLETEDPhase 4

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268 · Impetigo, Folliculitis, and more

COMPLETEDPhase 2/3

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032 · Impetigo

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 10, 2013Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1

Start dateNov 2008

Last updatedJun 10, 2013

Condition

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2013Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions